BioGeneric Pharma

What BioGeneric Pharma does

BioGeneric Pharma S.A.E (BGP) is an Egypt-based international biopharmaceutical company focused on the development, production, analytical testing, and marketing of therapeutic recombinant proteins, monoclonal antibodies, vaccines, and biosimilars. The company operates a state-of-the-art cGMP-compliant manufacturing facility in the 10th of Ramadan Industrial City, Egypt, combining upstream biomanufacturing (25L wave to 2,000L stirred-tank single-use bioreactors plus customized perfusion bioreactors), downstream purification (dual-use Chrome/TFF, nanofiltration, UF/DF), fill & finish across vials/prefilled syringes/cartridges, 1,100m2 GLP/cGMP quality control labs across approximately 20 specialized areas, and 1,825m2 of temperature-controlled warehousing. The technical platform is underpinned by an Integrated Management System covering ISO 9001, ISO 14001, ISO 45001, ISO 27001, and PAS 99, with 21 CFR Part 11-compliant electronic QMS/LIMS/ERP/BMS and compliance with FDA cGMP, EMA, and WHO standards.

BGP monetizes through six revenue streams: (1) proprietary biosimilar product sales targeting autoimmune, endocrinology, oncology, haematology, and vaccine indications; (2) full-service contract manufacturing for multinational biopharma; (3) toll manufacturing leveraging its vial line and single-use technology platforms; (4) in-licensing of pioneering or patent-protected products for MEA commercialization; (5) out-licensing of its own products to regional partners for distribution and co-marketing; and (6) contract QC analysis. The go-to-market is enterprise B2B, with dedicated business development and export managers, regional partner networks, and direct engagement with government health authorities across Africa and the Middle East. BGP was nominated by WHO in June 2021 as a technology recipient of the mRNA vaccine technology transfer hub, with operational training received from Afrigen Biologics in August 2022, positioning the company as a continental hub for biosimilar and vaccine sovereignty.

Name

BioGeneric Pharma

Legal name

BioGeneric Pharma S.A.E

Website

https://biogenericpharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

101–250 employees

Short description

BioGeneric Pharma is an Egypt-based biopharmaceutical company operating a cGMP-compliant contract manufacturing facility for biosimilars, vaccines, and recombinant proteins, serving multinational pharma, regional licensing partners, and government health buyers across EMEA, Africa, and FDA markets.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIABAI

Contract Development & Manufacturing for Generics (CDMO/CMO)

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYHLAGAHAL

GMP Scale-Up, Tech Transfer & Process Validation (PPQ)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAIALAD

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

SECONDARYHLAAAEAK

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

• Biopharmaceutical manufacturing
• Biosimilars production
• Contract manufacturing organization
• MRNA vaccine technology
• Vaccines and biologics

Headquarters

HQ city

Cairo

HQ country

Egypt

HQ region

Africa

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Biosimilar Product Sales: BGP develops and commercializes its own therapeutic recombinant proteins, monoclonal antibodies, and vaccines targeting autoimmune diseases, endocrinology, oncology, haematology, and vaccines. Revenue generated from marketing these proprietary biosimilar products, primarily targeting off-patent biologics for EMEA and FDA markets.
2. Contract Manufacturing Services (CMO): Full contract manufacturing services to biopharmaceutical companies seeking a flexible and highly qualified CMO. Services include biomanufacturing, fill & finish, toll manufacturing, and secondary packaging. BGP offers cGMP manufacturing to multinational corporations and large biopharma organizations outsourcing production.
3. Toll Manufacturing: Toll manufacturing services where BGP processes client-owned products using its vial line (high capacity) and single-use technology lines, accommodating various sizes and formats including vials, prefilled syringes, and cartridges.
4. In-licensing: BGP actively seeks strategic collaborations with companies interested in out-licensing pioneering or patent-protected products. BGP takes products through full lifecycle stages from development to commercialization, either exclusively or via co-marketing arrangements.
5. Out-licensing: BGP offers out-licensing of its own developed products, seeking collaboration with companies interested in joint development, registration, marketing, and distribution in specific regions.
6. Quality Control / Contract Analysis: Contract analysis and quality control testing services to external clients, leveraging BGP's 1100m2 GLP/cGMP-compliant QC labs capable of testing monoclonal antibodies, insulin, proteins, vaccines, cell & gene therapies, excipients, and adjuvants.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

BioGeneric Pharma S.A.E (BGP) develops, produces, analyzes, and markets therapeutic recombinant proteins, monoclonal antibodies and vaccines (biosimilars and novel products) using a cGMP-compliant single-use technology manufacturing platform located at 10th of Ramadan Industrial City, Egypt. In parallel, BGP offers contract manufacturing, toll manufacturing, fill & finish, GLP/cGMP quality control, and temperature-controlled warehousing services to biopharmaceutical clients across EMEA, FDA-markets, Africa and the Middle East.

Product overview

BioGeneric Pharma S.A.E is an international biopharmaceutical company operating as a full-service contract manufacturing organization (CMO) with a state-of-the-art facility in Egypt. The company offers an integrated portfolio combining manufacturing services (Biomanufacturing, Fill & Finish, Toll Manufacturing, Contract Manufacturing, Quality Control Labs, and Warehousing) with a diversified therapeutic products portfolio spanning Autoimmune Diseases, Endocrinology, Vaccines, Haematology, and Oncology. The company is strategically developing mRNA technology capabilities as part of the WHO technology transfer hub program. BGP leverages single-use technology (SUT) and operates under cGMP, FDA, EMA, and WHO quality standards.

Differentiator

Problem solved

Functional benefit

Products and services

• Biomanufacturing (Drug Substance) Biomanufacturing service for drug substance (DS) production using single-use technology (SUT) for biosimilars and vaccines under cGMP standards. Capabilities include upstream processing (25L wave bioreactors to 2000L stirred-tank bioreactors), downstream purification using dual-use Chrome/TFF systems, and nanofiltration / UF/DF processing. Targeted at biopharmaceutical clients and the company's own biosimilar pipeline.
• Fill & Finish Fill and finish service delivering sterile drug product in vials, prefilled syringes (PFS) and cartridges using state-of-the-art single-use technology and a high-capacity vial line for cGMP-compliant biologic products. Targeted at biopharmaceutical clients needing flexible format fill-finish of biosimilars and vaccines.
• Toll Manufacturing Toll manufacturing service in which BGP processes client-owned drug substance and drug product using its high-capacity vial line and single-use technology platforms across various sizes and formats — vials, prefilled syringes and cartridges. Targeted at biopharmaceutical companies requiring outsourced processing capacity.
• Contract Manufacturing Full contract manufacturing service for biopharmaceutical companies seeking a flexible and qualified CMO. Includes development and GMP-compliant manufacturing of proprietary products alongside outsourced production for multinational pharmaceutical corporations. Targeted at biopharma sponsors requiring outsourced manufacturing capacity.
• Quality Control Labs Quality control laboratory services spanning 1,100m² with ~20 specialized areas, GLP and cGMP compliant (Class D/C/B environments). Capabilities include physicochemical assays, immunoassays, microbiological assays and bioassays (in-vitro and in-vivo) for monoclonal antibodies, insulin, vaccines, cell & gene therapeutics, excipients and adjuvants. Offered both internally and as contract analysis for external clients.
• Warehousing Temperature-controlled warehousing covering 1,825m² with 1,750 Euro standard pallet locations across three temperature ranges — 15–25°C (975m²), 2–8°C (580m²), and –20°C (270m²) — with continuous monitoring and ERP/WMS integration. Targeted at biopharmaceutical clients requiring compliant storage of drug substance and drug product.
• mRNA Technology Platform An R&D and manufacturing platform for development of mRNA vaccines and therapeutics, with focus areas spanning COVID-19 vaccines, non-COVID vaccines, cancer therapeutics and gene editing applications. Established through BGP's nomination as a technology recipient under the WHO mRNA technology transfer hub program. Targeted at global public health partners and biopharma collaborators developing novel mRNA products.
• Autoimmune Diseases Products Proprietary biosimilar products targeting autoimmune diseases, developed and manufactured by BGP under cGMP standards for EMEA and FDA regulatory markets.
• Endocrinology Products Proprietary biosimilar products targeting endocrine disorders, including insulin and other therapeutic recombinant proteins, developed and manufactured by BGP under cGMP standards.
• Vaccines Vaccines developed through BGP's cutting-edge research, rigorous quality control and advanced cGMP manufacturing processes, including mRNA-based candidates via the WHO-nominated mRNA technology transfer hub program. Targeted at public health immunization programs and global vaccine markets.
• Haematology Products Proprietary biosimilar products targeting haematologic conditions, developed and manufactured by BGP under cGMP standards.
• Oncology Products Proprietary biosimilar products targeting oncology, including cancer therapeutics leveraging BGP's mRNA platform capabilities, developed and manufactured under cGMP standards.

Quantifiable outcome

• mRNA vaccine technology transfer hub nomination by WHO (2021)
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Seven partnerships are on record, tiered core.

• Africa CDC (Africa Centres for Disease Control and Prevention)coreStrategic or Co-development Partner · 7 February 2023Africa CDC visited BGP on 7 February 2023, demonstrating interest in BGP's capabilities for vaccine production and biopharmaceutical manufacturing capacity on the African continent.
• WHO (World Health Organization)coreStrategic or Co-development Partner · 21 June 2021BGP was nominated by WHO to be a technology recipient of the mRNA platform as part of the WHO mRNA vaccine technology transfer hub program. Announced on 21 June 2021, the hub is located at Afrigen in Cape Town, South Africa. BGP participates in sharing expertise, optimizing manufacturing processes, contributing to clinical trials, data analysis, and building capacity for mRNA technology. WHO Director General Dr. Tedros Adhanom visited BGP facilities in October 2022. WHO Egypt country office, EMRO, LPA unit, PQ team, and Geneva headquarters have also conducted multiple visits to BGP.
• Afrigen Biologics (South Africa)coreStrategic or Co-development Partner · 21 June 2021Afrigen Biologics hosts the WHO mRNA vaccine technology transfer hub in Cape Town, South Africa. In August 2022, a team from BioGeneric Pharma travelled to Afrigen Biologics to receive their first training in mRNA technology. BGP is a spoke (technology recipient) within this hub network.
• MPP (Medicines Patent Pool)coreStrategic or Co-development Partner · 21 June 2021MPP (Medicines Patent Pool) collaborates with WHO on the mRNA technology transfer hub. MPP representatives participated in follow-up visits to BGP alongside WHO Egypt country office, EMRO, and Geneva headquarters to advance mRNA technology transfer.
• EDA (Egyptian Drug Authority)coreOthersEDA (Egyptian Drug Authority) participates in regulatory visits to BGP facilities alongside WHO teams. EDA collaborates on PQ (Prequalification) processes and regulatory affairs, supporting BGP's compliance with international pharmaceutical standards.
• WHO EMRO (WHO Eastern Mediterranean Regional Office)coreStrategic or Co-development PartnerWHO EMRO conducted multiple visits to BGP facilities as part of the mRNA technology transfer program and regulatory prequalification assessment. EMRO's LPA (Local Production and Assistance) unit is actively involved in supporting BGP's development as a regional manufacturing hub.
• Pharmaceutical Companies (Undisclosed Partners)coreChannel Partner/ Reseller/ DistributorBGP is building networks and pursuing collaborations with biopharmaceutical companies for in-licensing and out-licensing arrangements. BGP aims to reinforce its in-licensing policy, especially in the Middle East & Africa region, through agreements with world-leading companies.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Catalent: Major pharma CDMO providing biologics, fill-finish and oral dose manufacturing to global pharma clients. Comparable as a contract manufacturing partner serving multinational biopharma companies under cGMP.
• Samsung Bioepis: Biosimilar-focused developer and manufacturer of monoclonal antibody biosimilars across immunology, oncology and ophthalmology. Comparable to BGP's biosimilar development-and-manufacturing strategy targeting autoimmune and oncology indications.
• Lonza Group: Global leader in biologics CDMO services, including mammalian and microbial manufacturing, fill-finish and cell & gene therapy. Directly comparable as a CMO partner for biopharmaceutical companies outsourcing biologic production under cGMP.
• Samsung Biologics: One of the world's largest biologics contract development and manufacturing organizations, offering mammalian-cell biomanufacturing, fill-finish and QC at multi-site scale. Comparable to BGP as a biologics CDMO serving global pharma clients under cGMP, although at vastly greater scale.
• Celltrion: South Korean biopharmaceutical company developing and manufacturing biosimilars (mAbs, immunology, oncology) for global markets. Comparable to BGP's proprietary biosimilar portfolio across autoimmune and oncology indications.
• AGC Biologics: Global biologics CDMO offering mammalian and microbial contract manufacturing, process development and biosimilar services. Directly comparable as a mid-sized biologics CMO serving biosimilar and vaccine developers.
• WuXi Biologics: End-to-end biologics CDMO offering discovery, development and manufacturing of monoclonal antibodies and biosimilars. Highly comparable business model combining proprietary biosimilar pipeline with CMO services under cGMP standards.

Regional players

• Aspen Pharmacare: Largest pharmaceutical manufacturer in Africa, producing generics, biologics and vaccines with strong presence across the African continent. Comparable to BGP as an Africa-headquartered biopharmaceutical manufacturer serving regional public-health demand.
• Eva Pharma: Egyptian pharmaceutical manufacturer producing generics, biosimilars and APIs for Africa and Middle East markets. Comparable to BGP as a domestic Egyptian pharma producer focused on regional access to affordable medicines and biosimilars.

Broad incumbents

• Serum Institute of India: World's largest vaccine manufacturer by doses, supplying global immunization programs including emerging markets. Comparable to BGP in vaccine manufacturing scale, emerging-market distribution and engagement with WHO and public-sector buyers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/story.php
• LinkedInlinkedin.com/company/biogeneric-pharma

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioGeneric Pharma